KONINKLIJKE PHILIPS NV (PHI1.DE) Fundamental Analysis & Valuation

FRA:PHI1 • NL0000009538

Current stock price

25.27 EUR
+0.5 (+2.02%)
Last:

This PHI1.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

4

1. PHI1.DE Profitability Analysis

1.1 Basic Checks

  • In the past year PHI1 was profitable.
  • PHI1 had a positive operating cash flow in the past year.
  • The reported net income has been mixed in the past 5 years: PHI1 reported negative net income in multiple years.
  • PHI1 had a positive operating cash flow in 4 of the past 5 years.
PHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFPHI1.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 2B 4B

1.2 Ratios

  • PHI1's Return On Assets of 3.32% is in line compared to the rest of the industry. PHI1 outperforms 47.62% of its industry peers.
  • PHI1's Return On Equity of 8.17% is fine compared to the rest of the industry. PHI1 outperforms 60.32% of its industry peers.
  • The Return On Invested Capital of PHI1 (5.16%) is comparable to the rest of the industry.
  • PHI1 had an Average Return On Invested Capital over the past 3 years of 3.27%. This is significantly below the industry average of 10.15%.
  • The last Return On Invested Capital (5.16%) for PHI1 is above the 3 year average (3.27%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROIC 5.16%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.27%
ROIC(5y)N/A
PHI1.DE Yearly ROA, ROE, ROICPHI1.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 20

1.3 Margins

  • Looking at the Profit Margin, with a value of 5.02%, PHI1 is in line with its industry, outperforming 46.03% of the companies in the same industry.
  • PHI1's Profit Margin has declined in the last couple of years.
  • PHI1's Operating Margin of 7.98% is in line compared to the rest of the industry. PHI1 outperforms 44.44% of its industry peers.
  • PHI1's Operating Margin has declined in the last couple of years.
  • With a Gross Margin value of 45.18%, PHI1 is not doing good in the industry: 76.19% of the companies in the same industry are doing better.
  • PHI1's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
OM growth 3YN/A
OM growth 5Y-5.27%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
PHI1.DE Yearly Profit, Operating, Gross MarginsPHI1.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30 40

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

2

2. PHI1.DE Health Analysis

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) below the Cost of Capital (WACC), PHI1 is destroying value.
  • Compared to 1 year ago, PHI1 has more shares outstanding
  • Compared to 5 years ago, PHI1 has more shares outstanding
  • PHI1 has a worse debt/assets ratio than last year.
PHI1.DE Yearly Shares OutstandingPHI1.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M
PHI1.DE Yearly Total Debt VS Total AssetsPHI1.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

2.2 Solvency

  • PHI1 has an Altman-Z score of 2.02. This is not the best score and indicates that PHI1 is in the grey zone with still only limited risk for bankruptcy at the moment.
  • PHI1 has a Altman-Z score of 2.02. This is comparable to the rest of the industry: PHI1 outperforms 42.86% of its industry peers.
  • The Debt to FCF ratio of PHI1 is 16.37, which is on the high side as it means it would take PHI1, 16.37 years of fcf income to pay off all of its debts.
  • PHI1 has a Debt to FCF ratio of 16.37. This is in the lower half of the industry: PHI1 underperforms 60.32% of its industry peers.
  • PHI1 has a Debt/Equity ratio of 0.63. This is a neutral value indicating PHI1 is somewhat dependend on debt financing.
  • PHI1 has a worse Debt to Equity ratio (0.63) than 68.25% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Altman-Z 2.02
ROIC/WACC0.82
WACC6.26%
PHI1.DE Yearly LT Debt VS Equity VS FCFPHI1.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

2.3 Liquidity

  • PHI1 has a Current Ratio of 1.32. This is a normal value and indicates that PHI1 is financially healthy and should not expect problems in meeting its short term obligations.
  • The Current ratio of PHI1 (1.32) is comparable to the rest of the industry.
  • PHI1 has a Quick Ratio of 1.32. This is a bad value and indicates that PHI1 is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.94, PHI1 is doing worse than 61.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.32
Quick Ratio 0.94
PHI1.DE Yearly Current Assets VS Current LiabilitesPHI1.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PHI1.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has been growing slightly by 6.11% over the past year.
  • Measured over the past years, PHI1 shows a decrease in Earnings Per Share. The EPS has been decreasing by -6.62% on average per year.
  • Looking at the last year, PHI1 shows a decrease in Revenue. The Revenue has decreased by -1.03% in the last year.
  • Measured over the past years, PHI1 shows a small growth in Revenue. The Revenue has been growing by 0.59% on average per year.
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
Revenue 1Y (TTM)-1.03%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%

3.2 Future

  • Based on estimates for the next years, PHI1 will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.24% on average per year.
  • PHI1 is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 3.78% yearly.
EPS Next Y3.11%
EPS Next 2Y8.19%
EPS Next 3Y10.16%
EPS Next 5Y10.24%
Revenue Next Year1.3%
Revenue Next 2Y2.87%
Revenue Next 3Y3.49%
Revenue Next 5Y3.78%

3.3 Evolution

  • When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
PHI1.DE Yearly Revenue VS EstimatesPHI1.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 5B 10B 15B 20B 25B
PHI1.DE Yearly EPS VS EstimatesPHI1.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1 1.5 2

More info and screens

Find the best growth stocksShow best growing peers

4

4. PHI1.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • PHI1 is valuated rather expensively with a Price/Earnings ratio of 17.19.
  • Based on the Price/Earnings ratio, PHI1 is valued cheaper than 87.30% of the companies in the same industry.
  • The average S&P500 Price/Earnings ratio is at 27.87. PHI1 is valued slightly cheaper when compared to this.
  • Based on the Price/Forward Earnings ratio of 16.67, the valuation of PHI1 can be described as correct.
  • Based on the Price/Forward Earnings ratio, PHI1 is valued a bit cheaper than the industry average as 65.08% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of PHI1 to the average of the S&P500 Index (38.51), we can say PHI1 is valued rather cheaply.
Industry RankSector Rank
PE 17.19
Fwd PE 16.67
PHI1.DE Price Earnings VS Forward Price EarningsPHI1.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • PHI1's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. PHI1 is cheaper than 74.60% of the companies in the same industry.
  • The rest of the industry has a similar Price/Free Cash Flow ratio as PHI1.
Industry RankSector Rank
P/FCF 49.26
EV/EBITDA 11.38
PHI1.DE Per share dataPHI1.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PHI1 does not grow enough to justify the current Price/Earnings ratio.
PEG (NY)5.52
PEG (5Y)N/A
EPS Next 2Y8.19%
EPS Next 3Y10.16%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHI1.DE Dividend Analysis

5.1 Amount

  • No dividends for PHI1!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHI1.DE Fundamentals: All Metrics, Ratios and Statistics

KONINKLIJKE PHILIPS NV

FRA:PHI1 (4/17/2026, 7:00:00 PM)

25.27

+0.5 (+2.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-10
Earnings (Next)05-06
Inst Owners48.33%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap24.33B
Revenue(TTM)17.84B
Net Income(TTM)895.00M
Analysts74.67
Price Target29.23 (15.67%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0.35
Dividend Growth(5Y)216.55%
DP36.65%
Div Incr Years0
Div Non Decr Years1
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.02%
Min EPS beat(2)3.95%
Max EPS beat(2)14.1%
EPS beat(4)4
Avg EPS beat(4)17.83%
Min EPS beat(4)3.95%
Max EPS beat(4)31.04%
EPS beat(8)4
Avg EPS beat(8)2.84%
EPS beat(12)6
Avg EPS beat(12)6.47%
EPS beat(16)7
Avg EPS beat(16)6.93%
Revenue beat(2)0
Avg Revenue beat(2)-1.63%
Min Revenue beat(2)-2.4%
Max Revenue beat(2)-0.86%
Revenue beat(4)0
Avg Revenue beat(4)-1.8%
Min Revenue beat(4)-2.4%
Max Revenue beat(4)-0.86%
Revenue beat(8)0
Avg Revenue beat(8)-2.61%
Revenue beat(12)1
Avg Revenue beat(12)-2.36%
Revenue beat(16)2
Avg Revenue beat(16)-1.72%
PT rev (1m)-0.2%
PT rev (3m)5.58%
EPS NQ rev (1m)-0.95%
EPS NQ rev (3m)-33.29%
EPS NY rev (1m)-0.89%
EPS NY rev (3m)-0.71%
Revenue NQ rev (1m)-0.13%
Revenue NQ rev (3m)5.94%
Revenue NY rev (1m)0.01%
Revenue NY rev (3m)-1.39%
Valuation
Industry RankSector Rank
PE 17.19
Fwd PE 16.67
P/S 1.36
P/FCF 49.26
P/OCF 20.94
P/B 2.22
P/tB N/A
EV/EBITDA 11.38
EPS(TTM)1.47
EY5.82%
EPS(NY)1.52
Fwd EY6%
FCF(TTM)0.51
FCFY2.03%
OCF(TTM)1.21
OCFY4.78%
SpS18.52
BVpS11.38
TBVpS-0.92
PEG (NY)5.52
PEG (5Y)N/A
Graham Number19.4007 (-23.23%)
Profitability
Industry RankSector Rank
ROA 3.32%
ROE 8.17%
ROCE 7.33%
ROIC 5.16%
ROICexc 6.02%
ROICexgc 20.88%
OM 7.98%
PM (TTM) 5.02%
GM 45.18%
FCFM 2.77%
ROA(3y)-0.23%
ROA(5y)0.96%
ROE(3y)-0.52%
ROE(5y)1.86%
ROIC(3y)3.27%
ROIC(5y)N/A
ROICexc(3y)3.74%
ROICexc(5y)N/A
ROICexgc(3y)12.88%
ROICexgc(5y)N/A
ROCE(3y)4.66%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5Y-1.19%
ROICexc growth 3YN/A
ROICexc growth 5Y-4.56%
OM growth 3YN/A
OM growth 5Y-5.27%
PM growth 3YN/A
PM growth 5Y-6.05%
GM growth 3Y3.66%
GM growth 5Y-0.43%
F-Score7
Asset Turnover0.66
Health
Industry RankSector Rank
Debt/Equity 0.63
Debt/FCF 16.37
Debt/EBITDA 2.72
Cap/Depr 59.38%
Cap/Sales 3.75%
Interest Coverage 5.63
Cash Conversion 45.59%
Profit Quality 55.2%
Current Ratio 1.32
Quick Ratio 0.94
Altman-Z 2.02
F-Score7
WACC6.26%
ROIC/WACC0.82
Cap/Depr(3y)53.03%
Cap/Depr(5y)53.41%
Cap/Sales(3y)3.68%
Cap/Sales(5y)4%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)6.11%
EPS 3Y15.66%
EPS 5Y-6.62%
EPS Q2Q%-1.96%
EPS Next Y3.11%
EPS Next 2Y8.19%
EPS Next 3Y10.16%
EPS Next 5Y10.24%
Revenue 1Y (TTM)-1.03%
Revenue growth 3Y0.01%
Revenue growth 5Y0.59%
Sales Q2Q%1.05%
Revenue Next Year1.3%
Revenue Next 2Y2.87%
Revenue Next 3Y3.49%
Revenue Next 5Y3.78%
EBIT growth 1Y15922.2%
EBIT growth 3YN/A
EBIT growth 5Y-4.71%
EBIT Next Year68.02%
EBIT Next 3Y26.32%
EBIT Next 5Y17.86%
FCF growth 1Y-43.86%
FCF growth 3YN/A
FCF growth 5Y-22.31%
OCF growth 1Y-25.32%
OCF growth 3YN/A
OCF growth 5Y-15.14%

KONINKLIJKE PHILIPS NV / PHI1.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHI1.DE.


What is the valuation status for PHI1 stock?

ChartMill assigns a valuation rating of 4 / 10 to KONINKLIJKE PHILIPS NV (PHI1.DE). This can be considered as Fairly Valued.


What is the profitability of PHI1 stock?

KONINKLIJKE PHILIPS NV (PHI1.DE) has a profitability rating of 4 / 10.


What is the financial health of KONINKLIJKE PHILIPS NV (PHI1.DE) stock?

The financial health rating of KONINKLIJKE PHILIPS NV (PHI1.DE) is 2 / 10.


Can you provide the expected EPS growth for PHI1 stock?

The Earnings per Share (EPS) of KONINKLIJKE PHILIPS NV (PHI1.DE) is expected to grow by 3.11% in the next year.